What Eximo Medical does

Eximo Medical is an Israeli medical device company founded in 2011 and headquartered in Rehovot that developed the B-Laser, a novel laser-based catheter system for peripheral atherectomy treatment of peripheral arterial disease (PAD). The company's core technology is a hybrid catheter that uses laser energy to resect tissue in vascular and gastrointestinal endoluminal applications, with a specific design that allows interventionalists to clear all lesion types including in-stent restenosis (ISR) and lesions above and below the knee using a single device, while minimizing embolization risk. Clinical efficacy is supported by two peer-reviewed studies: the B-Laser IDE study (6-month results published in Catheterization and Cardiovascular Interventions, 2019) and the EX-PAD-03 trial (acute and 30-day results published in Cardiovascular Revascularization Medicine, 2020), both demonstrating reductions in plaque burden and high patency rates across all levels of calcification.

The company's business model centers on a single OEM/licensing partnership with AngioDynamics (NASDAQ: ANGO), which acquired the B-Laser technology in 2020 and commercializes it as the Auryon System through its direct enterprise sales force and global medical device distribution network. Under this arrangement, AngioDynamics is responsible for manufacturing, marketing, and distribution, targeting vascular surgeons, interventional cardiologists, and interventional radiologists in hospital and catheterization lab settings. Pricing is quote-based and not publicly disclosed, consistent with hospital procurement processes for capital medical equipment and disposables. Eximo Medical itself operates with 11-50 employees, and pre-acquisition funding totaled approximately $2.52 million across three rounds from Peregrine Ventures and Accelmed, reflecting a focused R&D and clinical-evidence-development profile rather than a large commercial sales organization. Following the 2020 acquisition by AngioDynamics, Eximo Medical's B-Laser technology is integrated into the Auryon System product line, and the company's independent operating trajectory is effectively subsumed within its parent.

Name

Eximo Medical

Website

https://eximomedical.com

Company type

Private

Founded year

2011

Operating status

Acquired

Headcount range

11–50 employees

Short description

Eximo Medical is an Israeli medical device developer of the B-Laser, a novel laser-based catheter for peripheral atherectomy in PAD treatment, now commercialized by AngioDynamics as the Auryon System for interventional specialists in hospital settings.

Ownership category

akta.pro rank

Product category

Peripheral Vascular Atherectomy Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC)

akta.pro secondary industry

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

Keywords

• Peripheral atherectomy devices
• Laser atherectomy catheters
• Peripheral arterial disease treatment
• Vascular intervention devices
• Minimally invasive catheters

Headquarters

HQ city

Rehovot

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Eximo Medical developed the B-Laser atherectomy technology which was commercialized through AngioDynamics as the Auryon System. Revenue is generated through the sale of medical devices (laser catheters and systems) to healthcare providers treating peripheral arterial disease.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Eximo Medical developed the B-Laser, a novel hybrid laser-based catheter system for peripheral atherectomy procedures used in treating peripheral arterial disease (PAD). The catheter technology is designed to clear all lesion types — including in-stent restenosis (ISR), calcified lesions, and lesions above and below the knee — using a single device while minimizing the risk of embolization. The technology is commercialized through AngioDynamics under the Auryon System brand.

Product overview

Eximo Medical developed the B-Laser, a novel laser-based atherectomy device for treating peripheral arterial disease (PAD). The B-Laser technology was the foundational innovation that powered AngioDynamics' commercial Auryon System. The company specialized in minimally invasive laser-based catheter technology for vascular interventions, targeting treatment of complex lesions including in-stent restenosis and calcified plaque in the peripheral vascular system.

Differentiator

Problem solved

Functional benefit

Brands

• Auryon System: Laser atherectomy system for peripheral arterial disease (PAD) treatment. Originally developed by Eximo Medical as the B-Laser, the technology was acquired by AngioDynamics and integrated into the Auryon System product line. The system is indicated for treating all lesion types including in-stent restenosis (ISR), above and below the knee, with minimized risk of embolization.
• B-Laser

Products and services

• B-Laser Atherectomy Device A novel laser-based catheter system developed by Eximo Medical for peripheral atherectomy treatment of peripheral arterial disease (PAD). The device uses laser energy to clear various lesion types including in-stent restenosis (ISR), calcified plaque, and lesions both above and below the knee, with 2.0mm and 2.35mm catheter sizes specifically indicated for ISR. The technology was incorporated into AngioDynamics' Auryon System for commercial deployment.

Quantifiable outcome

• Reductions in plaque burden and high patency rates demonstrated across all levels of calcification and types of lesions
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• AngioDynamicscoreOEM/ Whitelabel/ Licensing PartnerAngioDynamics commercializes Eximo Medical's B-Laser atherectomy technology under the brand name Auryon System. The partnership involves technology licensing and commercialization rights, with AngioDynamics responsible for manufacturing, marketing, and distribution of the peripheral atherectomy device. Clinical trials referenced in marketing materials (B-Laser IDE study and EX-PAD-03 trial) were conducted to support regulatory approval and commercialization.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• AngioDynamics: AngioDynamics is both the acquirer of Eximo's B-Laser technology and the entity now commercializing it under the Auryon brand, making it the operational peer through which Eximo's technology reaches the market.
• Avinger: Avinger markets the Pantheris lumivascular (image-guided) atherectomy catheter for PAD — an emerging direct competitor targeting the same single-device, minimal-embolization positioning that Eximo's B-Laser emphasizes.
• Penumbra: Penumbra's Indigo mechanical thrombectomy and catheter-based peripheral vascular portfolio compete head-to-head with Eximo/B-Laser in the cath lab and for PAD and venous interventions.
• Cardiovascular Systems (Abbott): CSI (now part of Abbott) commercialized the Diamondback 360 orbital atherectomy system for PAD, including calcified peripheral lesions — a directly competing energy-based atherectomy modality targeting the same vascular specialists and patient population.
• Philips (Spectranetics): Philips acquired Spectranetics, which markets the Turbo-Elite and Turbo-Power excimer laser atherectomy systems — the closest direct competitor to Eximo's B-Laser in laser-based peripheral atherectomy for PAD and in-stent restenosis.
• Shockwave Medical (Johnson & Johnson): Shockwave's intravascular lithotripsy (IVL) system treats calcified peripheral lesions using a different energy modality but in the same cath-lab PAD workflow, increasingly competing for share against laser-based atherectomy including Auryon/B-Laser.
• Boston Scientific: Boston Scientific markets rotational atherectomy (Rotablator), the Jetstream atherectomy system, and peripheral ELCA laser catheters, making it a broad but direct peer across multiple atherectomy modalities used by the same interventional cardiology and vascular surgery call points as Eximo's B-Laser.

Broad incumbents

• Medtronic: Medtronic is a broad incumbent in peripheral vascular intervention with a portfolio that competes for the same interventional radiology and vascular surgery budget that Auryon/B-Laser targets across above- and below-knee PAD.
• Terumo: Terumo competes broadly in peripheral vascular intervention and interventional radiology with guidewires, catheters, and embolic-protection products used in the same PAD procedures served by Eximo's B-Laser.
• BD (Becton Dickinson): BD's peripheral intervention and vascular access franchises compete indirectly with Eximo's catheter-based atherectomy in the same hospital and cath-lab accounts, while its broader surgical and endovascular portfolio addresses adjacent vascular procedure budgets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xtwitter.com/AuryonPad
• Facebookbusiness.facebook.com/angiodynamics
• LinkedInlinkedin.com/company/eximo-medical

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eximo Medical